476 PFS by patient subgroup for standard chemotherapies in...

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

I. Bondarenko, J. Glaspy, A. Brufsky, O. Lipatov, E.A. Perez, S. Chan, X. Zou, S.C. Phan, N.J. Robert, V. Dieras
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70497-3
File:
PDF, 45 KB
english, 2010
Conversion to is in progress
Conversion to is failed